MedTrace Logo

rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers

NCT04180969 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-04-13

No results posted yet for this study

Summary

This study will be conducted with healthy male and female participants. Aim 1 will determine during sham repetitive transcranial magnetic stimulation (rTMS) how a drug stressor combination (yohimbine + hydrocortisone) relative to placebo alters : (1a) impulsivity; (1b) mood; and (1c) physiology. Aim 2 will determine whether active rTMS over the medial prefrontal cortex alters the effects of stress-exposure on (2a) decision-making, (2b) mood, and (2c) biomarkers of stress.

Conditions

  • Stress
  • Healthy

Interventions

DRUG

yohimbine + hydrocortisone

yohimbine 54mg + hydrocortisone 20mg oral

DEVICE

medial prefrontal cortex rTMS

1 Hz mPFC rTMS

DRUG

Placebo oral tablet

placebo stressor

DEVICE

sham rTMS

sham mPFC rTMS

Sponsors & Collaborators

  • Wayne State University

    lead OTHER

Principal Investigators

  • Mark K Greenwald, PhD · Wayne State University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-10
Primary Completion
2023-04-10
Completion
2023-04-10

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04180969 on ClinicalTrials.gov